TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
The Medtronic CoreValve Evolut and the Edwards Lifesciences Sapien 3 TAVR valves.

TAVR's success has changed how cardiologists and surgeons view aortic valve replacement

The standard-of-care thinking on TAVR has shifted from getting a valve implanted and managing immediate complications to looking decades down the road and considering the patient's long-term health. 

August 31, 2022
ESC Congress 2022 European Society of Cardiology. 6 key sessions from ESC Congress 2022: TAVR mortality, AI vs. sonographers, radial vs. femoral access and more

6 key sessions from ESC Congress 2022: TAVR mortality, AI vs. sonographers, radial vs. femoral access and more

ESC Congress 2022, the annual meeting of the European Society of Cardiology, was jam-packed with eye-opening new research from many of the leading voices in cardiovascular and vascular medicine. These six sessions were just some of the weekend's many highlights. 

August 29, 2022
TAVR has attracted many more patients to seek treatment for aortic valve disease, which has also helped feed more patients into surgical programs, despite TAVR now making up 84% of aortic valve replacement procedures.

Cardiac surgeons gaining procedural volume despite TAVR making up 84% of cases

A decade ago, when TAVR was first cleared by the FDA, surgeons had concern about losing business. But unexpectedly, TAVR has helped also gain heart surgery cases. 

August 5, 2022
A TAVR procedure being performed at Northwestern Medicine in Chicago.

VIDEO: How to build a structural heart program

Charles Davidson, MD, clinical chief of cardiology and medical director of the Bluhm Cardiovascular Institute, Northwestern University, explains what hospitals need to consider when starting a new structural heart program. 

June 23, 2022
Same-day discharge after TAVR is safe for low-risk patients, leads to considerable cost savings

Same-day discharge after TAVR is safe for low-risk patients, leads to considerable cost savings

Researchers aimed to shine light on this key topic, tracking data from nearly 200,000 patients. 

June 2, 2022
In a late-breaking long-term analysis presented at ACC 2022, the Medtronic CoreValve TAVR valve outperformed the surgical aortic valve replacement (SAVR) in terms of durability.

VIDEO: TAVR durability outperforms surgical valves

Michael J. Reardon, MD, professor of cardiothoracic surgery and Allison Family Distinguished chair of cardiovascular research at Houston Methodist DeBakey Heart and Vascular Center, presented pooled data at ACC.22 from the CoreValve SURTAVI trials that found transcatheter aortic valve replacement (TAVR) was more durable than surgical aortic valve replacement (SAVR) devices.

April 13, 2022
ci.jpg

Cardiology’s Challenge for the 2020s: Turning the Trend on Rising Mortality

The latest numbers on cardiovascular deaths put the focus on innovative ways to point the trend line down again.

November 1, 2019
Displaying 9 - 15 of 15

Around the web

Cardiovascular Business
FDA announces new recall of delivery catheters after patient’s death

The recall includes specific lots of five different medical devices used to treat stroke and other neurovascular diseases.

Cardiovascular Business
FDA warns against use of troubled heart devices, citing ‘continued concerns’ after multiple recalls

The agency is urging healthcare providers to transition away from these devices and seek out alternatives. It is even working with other manufacturers to try and get similar products on the market as quickly as possible. 

Cardiovascular Business
The push for an independent cardiology board continues

Jeffrey Kuvin, MD, one of the leading voices behind efforts to create a new Board of Cardiovascular Medicine, spoke with Cardiovascular Business about where things stand today.

Design by Adaptive Theme
Trimed Popup
Trimed Popup